Though at this point of time I am not doing any work related to my core expertise in which I had spent 4 years of my initial days......what is fascinating me now a days is that Bispecific and Antibody- Drug conjugates are the talk of the town, there are so many partnership deals happening in this space and we need to just see if Roche with its first Antoibody drug conjugate TDM1 will make the difference and will there be shift in the SOC. Roche with its correct strategies in place has monopolized the market and for the next 15-20 years secured its position in the space. Sometime I feel like going back to Research and start working again with some new technologies.
No comments:
Post a Comment